{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:08:37Z","timestamp":1770840517720,"version":"3.50.1"},"reference-count":53,"publisher":"Portland Press Ltd.","issue":"8","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Neurotensin and xenin possess antidiabetic potential, mediated in part through augmentation of incretin hormone, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), action. In the present study, fragment peptides of neurotensin and xenin, acetyl-neurotensin and xenin-8-Gln, were fused together to create Ac-NT\/XN-8-Gln. Following assessment of enzymatic stability, effects of Ac-NT\/XN-8-Gln on in vitro \u03b2-cell function were studied. Subchronic antidiabetic efficacy of Ac-NT\/XN-8-Gln alone, and in combination with the clinically approved GLP-1 receptor agonist exendin-4, was assessed in high-fat fed (HFF) mice. Ac-NT\/XN-8-Gln was highly resistant to plasma enzyme degradation and induced dose-dependent insulin-releasing actions (P&amp;lt;0.05 to P&amp;lt;0.01) in BRIN-BD11 \u03b2-cells and isolated mouse islets. Ac-NT\/XN-8-Gln augmented (P&amp;lt;0.001) the insulinotropic actions of GIP, while possessing independent \u03b2-cell proliferative (P&amp;lt;0.001) and anti-apoptotic (P&amp;lt;0.01) actions. Twice daily treatment of HFF mice with Ac-NT\/XN-8-Gln for 32 days improved glycaemic control and circulating insulin, with benefits significantly enhanced by combined exendin-4 treatment. This was reflected by reduced body fat mass (P&amp;lt;0.001), improved circulating lipid profile (P&amp;lt;0.01) and reduced HbA1c concentrations (P&amp;lt;0.01) in the combined treatment group. Following an oral glucose challenge, glucose levels were markedly decreased (P&amp;lt;0.05) only in combination treatment group and superior to exendin-4 alone, with similar observations made in response to glucose plus GIP injection. The combined treatment group also presented with improved insulin sensitivity, decreased pancreatic insulin content as well as increased islet and \u03b2-cell areas. These data reveal that Ac-NT\/XN-8-Gln is a biologically active neurotensin\/xenin fusion peptide that displays prominent antidiabetic efficacy when administered together with exendin-4.<\/jats:p>","DOI":"10.1042\/bsr20211275","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:09:14Z","timestamp":1628539754000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel neurotensin\/xenin fusion peptide enhances \u03b2-cell function and exhibits antidiabetic efficacy in high-fat fed mice"],"prefix":"10.1042","volume":"41","author":[{"given":"Rachele A.","family":"Perry","sequence":"first","affiliation":[{"name":"Ulster University, School of Pharmacy and Pharmaceutical Sciences, Diabetes Research Group, Coleraine, Northern Ireland, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah. L.","family":"Craig","sequence":"additional","affiliation":[{"name":"Ulster University, School of Pharmacy and Pharmaceutical Sciences, Diabetes Research Group, Coleraine, Northern Ireland, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor A.","family":"Gault","sequence":"additional","affiliation":[{"name":"Ulster University, School of Pharmacy and Pharmaceutical Sciences, Diabetes Research Group, Coleraine, Northern Ireland, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Flatt","sequence":"additional","affiliation":[{"name":"Ulster University, School of Pharmacy and Pharmaceutical Sciences, Diabetes Research Group, Coleraine, Northern Ireland, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-964X","authenticated-orcid":false,"given":"Nigel","family":"Irwin","sequence":"additional","affiliation":[{"name":"Ulster University, School of Pharmacy and Pharmaceutical Sciences, Diabetes Research Group, Coleraine, Northern Ireland, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"2021111620513665000_B1","doi-asserted-by":"publisher","first-page":"22305","DOI":"10.1016\/S0021-9258(18)41670-5","article-title":"Identification of xenin, a xenopsin-related peptide, in the human gastric mucosa and its effect on exocrine pancreatic secretion","volume":"276","author":"Feurle","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2021111620513665000_B2","doi-asserted-by":"publisher","first-page":"e3006","DOI":"10.1002\/dmrr.3006","article-title":"Emerging therapeutic potential for xenin and related peptides in obesity and diabetes","volume":"34","author":"Craig","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"2021111620513665000_B3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fendo.2012.00143","article-title":"Neurotensin and its receptors in the control of glucose homeostasis","volume":"3","author":"Mazella","year":"2012","journal-title":"Front. Endocrinol."},{"key":"2021111620513665000_B4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1210\/en.2015-1600","article-title":"Neurotensin is coexpressed, coreleased, and acts together with GLP-1 and PYY in enteroendocrine control of metabolism","volume":"157","author":"Grunddal","year":"2016","journal-title":"Endocrinology"},{"key":"2021111620513665000_B5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.bcp.2012.04.015","article-title":"Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25","volume":"84","author":"Martin","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"2021111620513665000_B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1515\/hsz-2017-0136","article-title":"Locally produced xenin and the neurotensinergic system in pancreatic islet function and \u03b2-cell survival","volume":"399","author":"Khan","year":"2017","journal-title":"Biol. Chem."},{"key":"2021111620513665000_B7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/270183a0","article-title":"Specific localisation of neurotensin to the N cell in human intestine by radioimmunoassay and immunocytochemistry","volume":"270","author":"Polak","year":"1977","journal-title":"Nature"},{"key":"2021111620513665000_B8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2337\/db18-1009","article-title":"Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway","volume":"68","author":"Ratner","year":"2019","journal-title":"Diabetes"},{"key":"2021111620513665000_B9","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2337\/db11-1451","article-title":"Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes","volume":"61","author":"Wice","year":"2012","journal-title":"Diabetes"},{"key":"2021111620513665000_B10","doi-asserted-by":"publisher","first-page":"19842","DOI":"10.1074\/jbc.M110.129304","article-title":"Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism","volume":"285","author":"Wice","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021111620513665000_B11","doi-asserted-by":"publisher","first-page":"110523","DOI":"10.1016\/j.mce.2019.110523","article-title":"Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, \u03c8-xenin-6, on pancreatic islet function and metabolism","volume":"496","author":"Craig","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"2021111620513665000_B12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2337\/dc09-1499","article-title":"Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits","volume":"33","author":"Drucker","year":"2010","journal-title":"Diabetes Care."},{"key":"2021111620513665000_B13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1464-5491.2005.01461.x","article-title":"Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes","volume":"22","author":"Lindsay","year":"2005","journal-title":"Diabet. Med."},{"key":"2021111620513665000_B14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejphar.2007.05.010","article-title":"Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1","volume":"568","author":"Duffy","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"2021111620513665000_B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0014-2999(91)90819-C","article-title":"Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability","volume":"205","author":"Lugrin","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"2021111620513665000_B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/JOE-13-0617","article-title":"Characterisation of the biological activity of xenin-25 degradation fragment peptides","volume":"221","author":"Martin","year":"2014","journal-title":"J. Endocrinol."},{"key":"2021111620513665000_B17","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1210\/en.2016-1329","article-title":"Effects of peripheral neurotensin on appetite regulation and its role in gastric bypass surgery","volume":"157","author":"Ratner","year":"2016","journal-title":"Endocrinology"},{"key":"2021111620513665000_B18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.lfs.2003.05.009","article-title":"Metabolism and potency of xenin and of its reduced hexapseudopeptide psi fragment in the dog","volume":"74","author":"Feurle","year":"2003","journal-title":"Life Sci."},{"key":"2021111620513665000_B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1432-1033.1982.tb05913.x","article-title":"Synthesis and characterization of neurotensin analogues for structure\/activity relationship studies. Acetyl-neurotensin-(8\u201313) is the shortest analogue with full binding and pharmacological activities","volume":"124","author":"Granier","year":"1982","journal-title":"Eur. J. Biochem."},{"key":"2021111620513665000_B20","doi-asserted-by":"publisher","first-page":"e0152818","DOI":"10.1371\/journal.pone.0152818","article-title":"Biological activity and antidiabetic potential of C-terminal octapeptide fragments of the gut-derived hormone xenin","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS ONE"},{"key":"2021111620513665000_B21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.4239\/wjd.v6.i15.1285","article-title":"New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders","volume":"6","author":"Irwin","year":"2015","journal-title":"World J. Diabetes"},{"key":"2021111620513665000_B22","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.2337\/dbi16-0068","article-title":"Single-molecule combinatorial therapeutics for treating obesity and diabetes","volume":"66","author":"Tsch\u00f6p","year":"2017","journal-title":"Diabetes"},{"key":"2021111620513665000_B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"2021111620513665000_B24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00125-016-4186-y","article-title":"An enzymatically stable GIP\/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice","volume":"60","author":"Hasib","year":"2017","journal-title":"Diabetologia"},{"key":"2021111620513665000_B25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.peptides.2017.10.015","article-title":"A novel GLP-1\/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice","volume":"100","author":"Hasib","year":"2018","journal-title":"Peptides"},{"key":"2021111620513665000_B26","doi-asserted-by":"publisher","first-page":"e3106","DOI":"10.1002\/dmrr.3106","article-title":"Exendin-4(Lys 27 PAL)\/gastrin\/xenin-8-Gln: A novel acylated GLP-1\/gastrin\/xenin hybrid peptide that improves metabolic status in obese-diabetic (ob\/ob) mice","volume":"35","author":"Hasib","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"2021111620513665000_B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1065-6995(02)00255-X","article-title":"DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2\u2013Asp13)GIP","volume":"27","author":"Gault","year":"2003","journal-title":"Cell Biol. Int."},{"key":"2021111620513665000_B28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2337\/diab.45.8.1132","article-title":"Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion","volume":"45","author":"McClenaghan","year":"1996","journal-title":"Diabetes"},{"key":"2021111620513665000_B29","doi-asserted-by":"publisher","first-page":"e96863","DOI":"10.1371\/journal.pone.0096863","article-title":"Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy","volume":"9","author":"Moffett","year":"2014","journal-title":"PLoS ONE"},{"key":"2021111620513665000_B30","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.2337\/db15-0220","article-title":"A novel CCK-8\/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice","volume":"64","author":"Irwin","year":"2015","journal-title":"Diabetes"},{"key":"2021111620513665000_B31","doi-asserted-by":"publisher","first-page":"129917","DOI":"10.1016\/j.bbagen.2021.129917","article-title":"Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control","volume":"1865","author":"Craig","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"2021111620513665000_B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-2007-1018945","article-title":"Plasma glucose and insulin response to glucagon and arginine in Aston ob\/ob mice: evidence for a selective defect in glucose-mediated insulin release","volume":"14","author":"Flatt","year":"1982","journal-title":"Horm. Metab. Res."},{"key":"2021111620513665000_B33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/dom.12300","article-title":"Evidence for inhibitory autocrine effects of proinsulin C-peptide on pancreatic \u03b2-cell function and insulin secretion","volume":"16","author":"McKillop","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"2021111620513665000_B34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbagen.2013.08.022","article-title":"Mechanisms of toxicity by proinflammatory cytokines in a novel human pancreatic beta cell line, 1.1B4","volume":"1840","author":"Vasu","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111620513665000_B35","doi-asserted-by":"publisher","first-page":"113723","DOI":"10.1016\/j.bcp.2019.113723","article-title":"A GIP\/xenin hybrid in combination with exendin-4 improves metabolic status in db\/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice","volume":"171","author":"Craig","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"2021111620513665000_B36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.peptides.2016.06.001","article-title":"Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery","volume":"82","author":"Sterl","year":"2016","journal-title":"Peptides"},{"key":"2021111620513665000_B37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.peptides.2009.09.029","article-title":"Effect of intracerebroventricular infusion of neurotensin in glucose-dependent insulinotropic peptide secretion in dogs","volume":"31","author":"Yavropoulou","year":"2010","journal-title":"Peptides"},{"key":"2021111620513665000_B38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/cells2010124","article-title":"The anti-apoptotic role of neurotensin","volume":"2","author":"Devader","year":"2013","journal-title":"Cells"},{"key":"2021111620513665000_B39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.bbagen.2016.01.015","article-title":"A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties","volume":"1860","author":"Parthsarathy","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111620513665000_B40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1677\/JOE-10-0085","article-title":"Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety","volume":"207","author":"Taylor","year":"2010","journal-title":"J. Endocrinol."},{"key":"2021111620513665000_B41","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1210\/endo-105-1-256","article-title":"Effect of neurotensin on insulin, glucagon, and somatostatin release from isolated pancreatic islets","volume":"105","author":"Dolais-Kitabgi","year":"1979","journal-title":"Endocrinology"},{"key":"2021111620513665000_B42","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.biocel.2008.03.015","article-title":"Neurotensin protects pancreatic beta cells from apoptosis","volume":"40","author":"Coppola","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2021111620513665000_B43","doi-asserted-by":"publisher","first-page":"G301","DOI":"10.1152\/ajpgi.00383.2013","article-title":"Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes","volume":"306","author":"Chowdhury","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021111620513665000_B44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tem.2012.11.008","article-title":"Glucagon-like peptide 1 and appetite","volume":"24","author":"Dailey","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"2021111620513665000_B45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.npep.2017.01.007","article-title":"Central action of xenin affects the expression of lipid metabolism-related genes and proteins in mouse white adipose tissue","volume":"63","author":"Bhavya","year":"2017","journal-title":"Neuropeptides"},{"key":"2021111620513665000_B46","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1515\/hsz-2020-0195","article-title":"Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes","volume":"401","author":"English","year":"2020","journal-title":"Biol. Chem."},{"key":"2021111620513665000_B47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nature17662","article-title":"An obligatory role for neurotensin in high-fat-diet-induced obesity","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"key":"2021111620513665000_B48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/er.2012-1041","article-title":"Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots","volume":"34","author":"Hocking","year":"2013","journal-title":"Endocr. Rev."},{"key":"2021111620513665000_B49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"2021111620513665000_B50","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41366-018-0084-3","article-title":"The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery","volume":"42","author":"von Loeffelholz","year":"2018","journal-title":"Int. J. Obes. (Lond)"},{"key":"2021111620513665000_B51","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.bbrc.2009.10.054","article-title":"Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents","volume":"390","author":"Arakawa","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111620513665000_B52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4161\/isl.2.6.13619","article-title":"Increased \u03b2-cell volume in mice fed a high-fat diet: a dynamic study over 12 months","volume":"2","author":"Ahr\u00e9n","year":"2010","journal-title":"Islets"},{"key":"2021111620513665000_B53","doi-asserted-by":"publisher","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20211275\/919663\/bsr-2021-1275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20211275\/919663\/bsr-2021-1275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T21:07:52Z","timestamp":1637096872000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/41\/8\/BSR20211275\/229492\/A-novel-neurotensin-xenin-fusion-peptide-enhances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,27]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20211275","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,8]]},"article-number":"BSR20211275"}}